AN ACT relating to administrative regulations for medications for substance use disorder and declaring an emergency.

Create a new section of KRS Chapter 13A to find 201 KAR 9:270 and 201 KAR 20:065 deficient and void; create new sections of KRS Chapters 311, 313, 314, and 315 to establish that the State Board of Medical Licensure, Board of Dentistry, Kentucky Board of Nursing, and Kentucky Board of Pharmacy shall not promulgate administrative regulations that restrict or limit the prescribing, dispensing, or administering of buprenorphine-mono-product, buprenorphine-combined-with-naloxone, or any other Schedule III, IV, or V medication approved by the United States Food and Drug Administration for the treatment of a substance use disorder; EMERGENCY.

Introduced: January 13, 2026

Last action: January 13, 2026

To Committee On Committees (S)

Read the full text Kentucky Legislature LegiScan

AI-generated — always verify with primary sources

Plain-language summary

Beta

This bill cancels two existing state administrative regulations and prevents Kentucky medical, dental, nursing, and pharmacy licensing boards from creating rules that would restrict how certain medications used to treat substance use disorder — including buprenorphine — are prescribed, dispensed, or administered. It is filed as an emergency measure, meaning it would take effect immediately upon becoming law. The goal is to remove state-level regulatory barriers to FDA-approved addiction treatment medications. Who it may affect: Kentuckians being treated for substance use disorder, as well as doctors, dentists, nurses, and pharmacists who prescribe or dispense these medications.

Open official bill text (PDF)·Report a problem with the summary